Hexagon Nutrition IPO
Price band
₹42 – ₹45
Lot size
333 shares
Min investment
₹14,985
Issue size
₹138.87 Cr
IPO schedule
| Open date | 5 Jun 2026 |
| Close date | 9 Jun 2026 |
| UPI mandate cut-off | 9 Jun 2026 |
| Allotment finalisation | 10 Jun 2026 |
| Refund initiation | 11 Jun 2026 |
| Shares credited to demat | 11 Jun 2026 |
| Listing date | 12 Jun 2026 |
| Mandate end date | 24 Jun 2026 |
| Anchor lock-in (50%) | 9 Jul 2026 |
| Anchor lock-in (remaining) | 7 Sept 2026 |
Issue size
About Hexagon Nutrition
Hexagon Nutrition Limited is a research-oriented nutrition company engaged in the development, manufacturing, and marketing of a wide range of nutrition products. The company operates across the nutrition value chain, offering micronutrient premixes, therapeutic and clinical nutrition products, and solutions for food fortification and malnutrition. It provides customised vitamin and mineral premixes to domestic and international fast-moving consumer goods companies and also supplies micronutrient powders for public health programmes. Its product portfolio addresses various nutritional needs, including clinical nutrition and preventive healthcare. The company follows an integrated business model, with capabilities spanning research and development, production, and distribution, and focuses on quality-driven offerings. Revenue is primarily generated through the sale of these nutrition products across different customer segments, including institutional and commercial clients.
Strengths
- Integrated nutrition company with capabilities from R&D to manufacturing and marketing.
- Diverse product portfolio covering premixes, clinical, and therapeutic nutrition.
- Strong presence in micronutrient premixes for FMCG companies.
- Supplier to global public health programmes for micronutrient powders.
- Focus on research-driven and quality-oriented product development.
Risks
- Heavy dependence on the premix formulation segment for revenue.
- High revenue concentration from a limited number of customers.
- Exposure to raw material price volatility due to a lack of long-term contracts.
- Risk of product quality issues leading to liability and reputational damage.
- Dependence on successful R&D and new product commercialisation.
IPO information is sourced from public feeds and shown for general information only. It is not a recommendation to apply for this or any IPO. IPOs are equity investments and carry market risk; listing gains are not guaranteed and SME IPOs are especially volatile. Grey Market Premium (GMP) is unofficial and not endorsed by SEBI or the exchanges. Equity IPOs are applied for through a demat and trading account, not through mutual fund distribution services. Read the RHP and consult a SEBI-registered investment adviser before investing.